The July 2026 FDA peptide advisory committee: what's on the agenda.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet in July 2026 to review the 14 peptides that HHS Secretary RFK Jr. proposed removing from Category 2 in February. This is the procedural step that converts the HHS announcement into actual regulatory change — or doesn't.

The committee is advisory; the FDA makes the final determination. But PCAC recommendations carry weight, and when they're combined with HHS political direction, the ruling tends to follow.

What the committee will review

For each of the 14 peptides, PCAC will consider: the current state of safety and efficacy evidence, the feasibility of safe compounding at 503A and 503B scale, whether any preparation conditions (labeling, purity standards, prescribing limits) should apply, and whether there's a reasonable clinical need in a population the FDA-approved drug market isn't serving.

The evidence base differs sharply across the 14. GHK-Cu has decades of topical-use dermatology research; BPC-157 has hundreds of animal studies but thin human data. Some will likely get green-lit with conditions; others may stay on Category 2; a few could go back to Category 1 with minimal restrictions.

What a yes would mean

If FDA ratifies removal of a peptide from Category 2 after PCAC review, 503A pharmacies can resume compounding it for individual patients with a prescription. 503B outsourcing facilities can compound at scale. For compounded peptides with genuine therapeutic interest and research support (GHK-Cu, tesamorelin-adjacent work, potentially CJC-1295), this matters — it reopens legal access at compounding-pharmacy pricing.

It does not convert these peptides into FDA-approved drugs. There's no marketing authorization, no prescribing information, no approved indications. Physicians prescribe off-label, and pharmacies compound per prescription. Insurance coverage is typically absent for compounded preparations.

What a no would mean

Keeping a peptide on Category 2 maintains the status quo: no legal compounding, research-use-only sales by vendors under continuing FDA enforcement risk, no domestic patient access outside clinical trials.

What to watch specifically

Three peptides I'd watch closely:

**GHK-Cu (injectable)** — has the strongest evidence base across the list and the clearest case for safety at compounding scale. Most likely to be uncontroversial yes.

**BPC-157** — the highest political heat, thinnest rigorous human data, strongest biohacker advocacy. The ruling here will signal whether PCAC is weighing evidence quality or process speed.

**Thymosin alpha-1** — approved in 30+ countries for immune indications, with better clinical evidence than most of the list. A rejection here would suggest process-driven rather than evidence-driven decision-making.